Glipizide XL — Class II drug recall D-0010-2019
Terminated recall by Pfizer Inc., reported 2018-10-17, distributed nationwide. CGMP Deviations; rejected product was used to manufacture final bulk lot
| Recall number | D-0010-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer Inc., New York, NY, United States |
| Recall initiated | 2018-09-20 |
| Classified | 2018-10-09 |
| Reported by FDA | 2018-10-17 |
| Terminated | 2020-05-08 |
| Distributed | Nationwide (US) |
| Quantity | 7,777 bottles |
| Reason classes | cgmp |
| NDC | 59762-0541-02 |
| Lot numbers | T71137 |
| Expiration dates | 2022-02-20 |
Product
Glipizide XL (glipizide) extended-release tablets 5 mg 500-tablet bottle, Rx only Distributed by: Greenstone LLC. Peapack, NJ 07977 --- NDC 59762-0541-2
Reason for recall
CGMP Deviations; rejected product was used to manufacture final bulk lot
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0010-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.